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BACkgrounD: Nocardia species are rare, opportunistic organisms 
that cause disease in both immunocompetent and immunocompromised 
individuals.
oBJECTIvE: To investigate the clinical presentations of various 
Nocardia infections based on the 16S ribosomal RNA gene of the iso-
late, as well as related risk factors and susceptibility patterns to antimi-
crobial agents
METhoDS: Thirteen patients with a diagnosis of nocardiosis were 
included in the present study. Seven Nocardia species were identified 
by 16S ribosomal RNA. Susceptibility testing was performed using six 
antimicrobial agents.
rESulTS: Five patients were immunocompromised, and eight were 
immunocompetent with predisposing factors including cystic fibrosis, 
tuberculosis and ophthalmic infections. Nocardia caused pulmonary 
infections in eight patients (61.5%), invasive systemic infections in 
three patients (23%) and local (ophthalmic) infections in two patients 
(15.4%). In the patients with pulmonary disease, nocardiosis was 
caused by six species (Nocardia cyriacigeorgica, Nocardia otitidiscaviarum, 
Nocardia farcinica, Nocardia carnea, Nocardia testacea and Nocardia 
asiatica). The seventh species identified in the present study was 
Nocardia crassostreae.
DISCuSSIon: N crassostreae is a multidrug-resistant organism that 
was reported to be an emerging human pathogen causing invasive 
nocardiosis in a patient with non-Hodgkin’s lymphoma. N farcinica 
was isolated from blood in a patient with breast cancer. None of the 
Nocardia isolates were resistant to linezolid. One N otitidiscaviarum 
isolate was a multidrug-resistant organism. All patients in the present 
study were treated with the appropriate antibiotics and their condition 
resolved without further sequelae.
ConCluSIonS: The present study is the first report on N cras-
sostreae as a human pathogen. The detection of multidrug-resistant 
species necessitate molecular identification and susceptibility testing, 
and should be performed for all Nocardia infections. Nocardiosis mani-
fests various clinical features depending on the Nocardia species and 
underlying conditions.
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l’identification moléculaire et le profil de 
susceptibilité des espèces de Nocardia en clinique : 
l’émergence de la Nocardia crassostreae comme 
agent de nocardiose invasive
hISTorIQuE : Les espèces de Nocardia sont des organismes oppor-
tunistes rares qui sont pathogènes à la fois chez les personnes immuno-
compétentes et immunodéprimées.
oBJECTIF : Explorer la présentation clinique de diverses infections 
à Nocardia d’après le gène d’ARN ribosomique 16S de l’isolat, ainsi 
que les facteurs de risque connexes et les profils de susceptibilité aux 
antimicrobiens.
MÉThoDologIE : Treize patients ayant un diagnostic de nocardiose 
ont participé à la présente étude. Les chercheurs ont repéré sept espèces 
de Nocardia au moyen de l’ARN ribosomique 16S. Ils ont effectué les 
tests de susceptibilité à six antimicrobiens.
rÉSulTATS : Cinq patients étaient immunodéprimés et huit étaient 
immunocompétents, mais présentaient des facteurs de prédisposition, y 
compris la fibrose kystique, la tuberculose et des infections ophtalmiques. 
La Nocardia a provoqué des infections pulmonaires chez huit patients 
(61,5 %), des infections systémiques invasives chez trois patients (23 %) 
et des infections locales (ophtalmiques) chez deux patients (15,4 %). 
Chez les patients atteints d’une maladie pulmonaire, la nocardiose était 
attribuable à six espèces (Nocardia cyriacigeorgica, Nocardia otitidiscaviarum, 
Nocardia farcinica, Nocardia carnea, Nocardia testacea et Nocardia asiatica). 
La septième espèce observée dans la présente étude était la Nocardia cras-
sostreae.
EXPoSÉ : La N crassostreae, un organisme multirésistant considéré 
comme un agent anthropopathogène émergent, était responsable d’une 
nocardiose invasive chez un patient atteint d’un lymphome non hodgki-
nien. Les chercheurs ont isolé le N farcinica dans le sang d’un patient 
atteint d’un cancer du sein. Aucun des isolats de Nocardia n’était résis-
tant à la linézolide. Un isolat de N otitidiscaviarum était multirésistant. 
Tous les patients participant à la présente étude ont reçu un traitement 
aux antibiotiques pertinent et se sont rétablis sans autres séquelles.
ConCluSIon : La première étude est la première à faire état de la 
N crassostreae comme agent anthropopathogène. Pour déceler les espèces 
multirésistantes, il faut procéder à une identification moléculaire et à un 
test de susceptibilité, des mesures qu’il faudrait prendre à l’égard de 
toutes les infections à Nocardia. La nocardiose s’associe à diverses carac-
téristiques cliniques, selon l’espèce de Nocardia et les maladies sous-
jacentes.
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Nocardia are ubiquitous organisms distributed worldwide in the environment as saprophytic components of fresh and salt water, 
soil, dust, decaying vegetation and decaying fecal deposits from ani-
mals (1). Nocardia are rare opportunistic organisms that cause diseases 
in immunocompetent and immunocompromised individuals, and are 
reported in all ages and ethnic groups. Immunocompetent patients 
usually develop localized cutaneous lesions, such as cellulitis, abscesses 
or sporotrichoid forms (2), and endogenous endophthalmitis (3). 
However, most cases are reported in immunocompromised patients, 
and manifest as deep infections or disseminated diseases (4-6). Risk 
factors for infection with Nocardia include solid organ transplant 
(5,7-9) or bone marrow transplant recipients (10), patients with 
hematological diseases (11,12) and HIV infection (13-16). Pulmonary 
nocardiosis can be a cause of disease in populations with risk factors 
such as immunosuppression, malignancies and severe lung disease 
(17), patients with cystic fibrosis (18), and in patients with chronic 
obstructive pulmonary disease and bronchiectasis (19,20). Lung infec-
tions are frequent and, in many cases, disease can spread to the central 
nervous system, including the brain (4,21), with poor prognosis in 
some cases, irrespective of antimicrobial therapy (22).
Identification of clinical isolates beyond the genus level is import-
ant because Nocardia species differ in clinical spectrum and their sus-
ceptibility to antibiotics. The classic laboratory methods of 
identification, including direct examination and culture, are insuffi-
cient; therefore, sequence analysis of the 16S ribosomal (r)RNA gene 
is mainly used for the identification of Nocardia isolates to species level 
(23,24).
Trimethoprim-sulfamethoxazole has traditionally been the agent of 
choice for the treatment of nocardiosis, with alternative drugs including 
amikacin and imipenem (1,25). Resistance and therapeutic failure may 
occur, which necessitates a search for alternative agents. The aim of the 
present study was to investigate the clinical presentations of various 
Nocardia infections based on the 16S rRNA gene of the isolate, related 
risk factors and susceptibility patterns to various antimicrobial agents.
METhoDS
Patients
The present laboratory-based study was approved by the Scientific 
Council and Ethics Committee of Hamad Medical Research Center, 
Doha, Qatar (proposal number 10174/10).
Thirteen patients of different nationalities with various clinical 
symptoms and risk factors admitted to Hamad Hospital, Doha, Qatar, 
were diagnosed with nocardial infections by the main Microbiology 
Laboratory of Hamad Medical Corporation from January 2006 to June 
2010. Patients’ clinical records, demographic data and treatment out-
comes were included in the present study. Information regarding sex, 
age, underlying conditions including history of immunosuppressant 
drug use, tuberculosis and malignancy were analyzed (Table 1). 
Disseminated nocardiosis was considered for infection of two organs or 
more, such as lungs, lymph nodes, brain or blood. The respiratory 
samples included sputum, endotracheal aspiration and bronchoalveo-
lar lavage. A diagnosis of pulmonary nocardiosis required at least one 
positive culture from respiratory samples, and the presence of clinical 
symptoms and an abnormal chest radiograph.
Isolation and identification of Nocardia species
A total of 13 clinical specimens positive for Nocardia species were 
recorded over a four-year period. Nocardia species were isolated and 
identified according to standard laboratory procedures. Identification 
of Nocardia species was based on Gram-positive branching, beaded and 
filamentous bacilli, and positive modified acid-fast stain results. The 
clinical specimens were generally cultured on chocolate agar and 
blood agar media, and incubated in both aerobic and anaerobic condi-
tions at 37°C. Characteristic dry, chalk-like Nocardia colonies appeared 
on aerobic cultures after three to seven days of incubation, depending 
on the species. Blood cultures were performed using the Bactec auto-
mated culturing system (BD Diagnostic Systems, USA).
Molecular analysis
The identities of the clinical isolates were further confirmed by 16S 
rRNA gene analysis (26). The DNA was isolated from freshly grown 
colonies using a MagNA Pure LC instrument in combination with 
MagNA Pure LC DNA isolation kit III according to the instructions 
of the manufacturer (Roche Diagnostics, The Netherlands). An 
approximately 500 bp fragment from the 5′ end of the 16S rRNA gene 
was amplified using polymerase chain reaction containing 1 U of 
FastStart Taq DNA polymerase (Roche Diagnostics), 0.2 mM dNTPs, 
1.5 mM MgCl2 and 0.5 µM of both amplification primers (forward: 
5′-CCT AAC ACA TGC AAG TCG ARC G-3′; reverse: 5′-CGT 
ATT ACC GCG GCT GCT-3′) in 1× polymerase chain reaction reac-
tion buffer. Cycling conditions were as follows: 30 s at 94°C, 30 s at 56°C 
and 1 min at 72°C repeated 30 times, preceded by a 10 min activation step 
at 94°C and followed by an additional 10 min elongation step at 72°C. 
The amplified product was purified using SPRI chemistry (AMPure, 
Beckman Coulter, The Netherlands) and subjected to DNA sequence 
analysis with the reverse amplification primer using the DYEnamic ET 
dye terminator kit (GE Healthcare, Belgium) as recommended. Sequence 
reaction products were purified using SPRI chemistry (CleanSeq Beckman 
Coulter) and analyzed on a MegaBACE 500 automated DNA analysis 
platform (GE Healthcare) using standard electrophoretic conditions. The 
obtained sequences were verified and manually corrected when necessary 
using MegaBACE Sequence Analyzer v3.0 (GE Healthcare). Sequences 
were then compared with the public DNA databases using the BLAST 
interface (www.ncbi.nlm.nih.gov/BLAST/).
Susceptibility testing
Antimicrobial susceptibility testing was performed using Etest (AB 
biodisk, Sweden). A suspension of the microorganism, with turbidity 
equivalent to 1.0 McFarland standard, was inoculated (150 µL/plate) 
by confluent swabbing on Mueller-Hinton agar plates. A maximum of 
two Etest strips were applied to each plate. Etest plates were incubated 
at 35°C and results were recorded after 48 h (or after 72 h if growth 
was insufficient after 48 h). The following antimicrobial agents were 
tested (concentration ranges): amikacin (0.016 µg/mL to 256 µg/mL), 
moxifloxacin (0.002 µg/mL to 32 µg/mL), cefotaxime (0.016 µg/mL to 
256 µg/mL), cotrimoxazole (0.002 µg/mL to 32 µg/mL), linezolid 
(0.016 µg/mL to 256 µg/mL) and imipenem (0.002 µg/mL to 32 µg/mL). 
Agents were determined by Etest for 13 Nocardia isolates from clinical 
specimens. Minimum inhibitory concentrations were determined 
according to manufacturer’s guidelines. Results were interpreted as 
susceptible, intermediate or resistant according the breakpoints rec-
ommended by the Clinical and Laboratory Standards Institute for 
Nocardia and other aerobic actinomycetes (27).
Beta-lactamase activity: All Nocardia clinical isolates were tested for 
beta-lactamase activity using the nitrocefin disk test
rESulTS
Microbiological investigation
A total of 13 Nocardia isolates were identified from 13 patients during 
the period January 2006 to June 2010. Molecular identification yielded 
Nocardia cyriacigeorgica (n=3; Genbank accession number JN041560), 
Nocardia otitidiscaviarum (n=2; Genbank accession number JN041512), 
Nocardia farcinica (n=3; Genbank accession number JN041682), 
Nocardia carnea (n=2; Genbank accession number JN041599) and one 
each of Nocardia asiatica, Nocardia crassostreae and Nocardia testacea 
(Genbank accession numbers JN041487, AY756548 and AB192415, 
respectively).
Clinical features
Demographic data and information pertaining to the source of isola-
tion, as well as the clinical symptoms of the patients yielding these 
isolates, are provided in Table 1. Thirteen patients (seven male and six 
female, 17 to 73 years of age) were diagnosed as having Nocardia infec-
tions. Five patients were immunocompromised, and eight were appar-
ently immunocompetent with predisposing factors such as cystic 
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fibrosis, tuberculosis and ophthalmic infections with no apparent risk 
factor. Nocardia caused pulmonary infection in eight patients (61.5%), 
invasive infections in three patients (23%) and local (ophthalmic) 
infections in two patients (15.4%). Pulmonary nocardiosis was found to 
be caused by N cyriacigeorgica, N otitidiscaviarum, N farcinica, N carnea, 
N testacea or N asiatica. Two Nocardia species were involved in oph-
thalmic infections (N otitidiscaviarum and N farcinica) and three spe-
cies caused invasive infections (N cyriacigeorgica, N farcinica and 
N crassostreae). Of the three patients with predisposing factors for 
invasive infections, two had non-Hodgkin’s lymphoma and were cur-
rently undergoing chemotherapy, and one had breast cancer and was 
also undergoing chemotherapy.
Invasive infections
Patients with non-hodgkin’s lymphomas (cases 1 and 11): Case 1 
was a female patient with a Nocardia cavitary lesion in the left upper 
lung lobe who developed an abscess approximately 3.5 cm in diameter 
with thick wall present at the left lumborum muscle at the level of L1 
vertebral body, as shown in magnetic resonance imaging (Figure 1). 
Under computed tomography (CT) guidance, a large-gauge needle was 
inserted into the abscess and a small amount of pus was aspirated and 
sent to the microbiology laboratory for microscopy and culture; the 
culture grew N cyriacigeorgica. The patient recovered after treatment 
with ceftriaxone and sulfamethoxazole-trimethoprim (cotrimoxazole) 
and is still doing well. In the other woman (case 11), a CT scan 
revealed a large, paravertebral abscess at the L3-L5 level, present in 
the left psoas muscle and compressing and displacing the left kidney. A 
catheter was inserted percutaneously into the abscess; more than 
50 mL of pus was aspirated and the catheter was left in situ for further 
drainage. The abscess extended outward and produced another abscess 
collection in the left lumborum muscle (Figure 2); the abscess was 
aspirated under CT guidance, and sent to the microbiology laboratory 
for microscopy and culture (the culture grew N crassostreae). There 
was no patient history of contact with or ingestion of molluscs. The 
patient improved after treatment with meropenem and trimethoprim-
sulfamethoxazole, but died later from progressive disease.
Blood stream infection: The third case of invasive nocardiosis was found 
in an immunocompromised patient with breast cancer undergoing 
Figure 1) Magnetic resonance image of a patient (case 1) with pulmonary 
nocardiosis and dissemination to an abscess approximately 3.5 cm in diam-
eter with thick wall (arrow) in the left lumborum muscle at level of L1 ver-
tebral body caused by Nocardia cyriacigeorgica
Figure 2) Computed tomography scan shows a large abscess caused by 
Nocardia crassostreae, in the left psoas muscle (solid arrow) extending 
outward and producing a multiloculated abscess (open arrow) in the left 
lumborum muscle (case 11) 
TAble 1
Clinical characteristics and outcome of 13 patients with nocardiosis
Case
Age, 
years/
sex
Patient 
origin Clinical diagnosis
Clinical 
specimen
16S rRNA 
identification 
(genus Nocardia) Treatment Outcome
1 42/F Qatar Non-Hodgkin’s lymphoma, abscess on back at L1 level Pus aspirate N cyriacigeorgica Ceftriaxone + SXT Recovered
2 33/M India Chest pain, pleural effusion, lingular infiltrates Sputum N cyriacigeorgica Azithromycin Recovered
3 36/M India Pulmonary infection mimicking tuberculosis Sputum N cyriacigeorgica NA NA
4 45/M India Corneal abscess Corneal 
scraping
N otitidiscaviarum Local gentamicin and 
levofloxacin eye drops
Recovered
5 17/F Qatar Cystic fibrosis with pneumonia BAL N otitidiscaviarum Clarithromycin + SXT, 
moxifloxacin
Recovered
6 50/F Qatar Conjunctivitis Conjunctival 
swab
N farcinica Fusidic acid + 
lomefloxacin
Recovered
7 68/M Qatar Renal transplant Sputum N farcinica Meropenem + SXT Recovered
8 50/F India Breast cancer on chemotherapy with central line-
related sepsis
Blood N farcinica SXT Recovered
9 30/M India Pulmonary tuberculosis, bronchiectasis Sputum N carnea Anti-TB Recovered
10 36/M Egypt Pulmonary infection mimicking tuberculosis Sputum N carnea NA NA
11 73/F Qatar Non-Hodgkin’s lymphoma, paravertebral abscess at 
L3-L5, on chemotherapy
CT-guided 
aspirated fluid
N crassostreae Meropenem + SXT Improved; died from 
progressive disease
12 34/M India Previous case of pulmonary tuberculosis Sputum N testacea None NA
13 44/F Syria Breast cancer with pulmonary infection Sputum N asiatica SXT Recovered
Anti-TB Antituberculosis treatment; BAL Bronchoalveolar lavage; CT Computed tomography; F Female; M Male; NA Not available; rRNA Ribosomal RNA; SXT 
Trimethoprim-sulfamethoxazole
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chemotherapy (case 8), who was diagnosed with N farcinica infection. 
She was successfully treated with trimethoprim-sulfamethoxazole.
Pulmonary nocardiosis
Pulmonary nocardiosis was diagnosed in eight patients in the present 
study. In case 3, an immunocompetent male patient with chest pain, 
pleural effusion and lingular infiltrates, a CT scan showed a small area 
of consolidation present in the inferior segment of lingula of the left 
lung, along with ill-defined hazy linear shadowing present at the per-
iphery of the lateral segment of the left lower lobe (Figure 3). Sputum 
culture grew N cyriacigeorgica, and the patient recovered after treat-
ment with azithromycin.
Antimicrobial susceptibility
The antimicrobial susceptibility patterns of the 13 Nocardia species for 
six antibacterial agents are summarized in Table 2. Growth inhibition 
ellipses were uniform and well delineated, and the points of intersec-
tion with the Etest strips were easy to determine, except for N otitidis-
caviarum (case 4), in which the mutant colonies appeared with 
cotrimoxazole Etest strips at a minimum inhibitory concentration of 
12 µg/mL. All Nocardia isolates were susceptible to linezolid, but 
showed various susceptibility patterns to other antimicrobial agents. 
The N crassostreae isolate (case 11) was resistant to amikacin, cefo-
taxime and imipenem. The N otitidiscaviarum isolate (case 4) was 
resistant to imipenem, cotrimoxazole and cefotaxime, and intermedi-
ate for moxifloxacin. N otitidiscaviarum isolate (case 5) was resistant to 
the antimicrobial agents cefotaxime and imipenem. Eight Nocardia 
isolates showed beta-lactamase activity by nitrocefin disk test. Positive 
reaction was demonstrated within 5 min. The nitrocefin test was nega-
tive for N carnea, N testacea and N asiatica, whereas N cyriacigeorgica 
isolates showed variability in the results of nitrocifin test, with one of 
the three strains being negative. Positive beta-lactamase Nocardia 
included N otitidiscaviarum and N crassostreae, which also exhibited 
resistance to cefotaxime and imipenem.
DISCuSSIon
Identification of Nocardia to species level using phenotyping is difficult 
(1,2). Sequencing of the 16S rRNA gene enables more accurate iden-
tification, and the application of this technique has resulted in the 
identification of new and clinically important species of Nocardia over 
the past 10 years (28-30). The number of reported clinical cases caused 
by opportunistic nocardiosis infections is constantly rising. Seven spe-
cies of Nocardia from 13 cases were reported in a relatively short period 
during the present study (Table 1). N cyriacigeorgica and N farcinica are 
the most common species associated with clinical specimens in Qatar, 
each represented by three cases, collectively constituting 46% of the 
cases. N cyriacigeorgica is frequently isolated from clinical specimens 
(31,32). The most frequently reported cases of N cyriacigeorgica consti-
tute disseminated infections with various risk factors including bacter-
emia in a renal transplant (33), brain abscess in HIV (34), endocarditis 
(35) and pulmonary infections (36). In the present study, N cyr-
iacigeorgica was isolated from pulmonary infections in two cases and 
one disseminated infection in a patient with non-Hodgkin’s lymph-
oma. N farcinica has been reported to be an increasing cause of local-
ized and disseminated infections in immunocompromised patients in 
recent years (37-39), but bacteremia remains a rare finding (40,41). In 
the present study, we reported a case of bacteremia in a 50-year-old 
woman with breast cancer undergoing chemotherapy. The second case 
was a pulmonary infection in a renal transplant patient, treated suc-
cessfully with meropenem/trimethoprim-sulfamethoxazole, whereas 
the third case was conjunctivitis in a patient with no apparent immune 
dysfunction. Although Nocardia infection of any type involving the 
eye is rare, several species have been diagnosed as a cause of keratitis 
(42); the isolation of N farcinica in the present study will be added as a 
possible etiological agent of eye infection. N otitidiscaviarum has been 
isolated from a fatal brain abscess in a patient with chronic obstructive 
pulmonary disease (22), in a case of bacteremia (43) and also from 
pulmonary infection (44); in the present study, this species was found 
in two cases: corneal abscess in an immunocompetent patient and 
severe pneumonia in a patient with cystic fibrosis. In a retrospective 
analysis that included 17 cystic fibrosis patients (18), five Nocardia 
species (including N otitidiscaviarum) were considered as colonizers 
and oral antibiotic therapy did not appear to affect the clinical out-
come. A patient with cystic fibrosis in the present study (case 5) was 
hospitalized for severe pneumonia that was treated successfully with 
clarithromycin, trimethoprim-sulfamethoxazole and moxifloxacin 
with clinical improvement and negative post-treatment sputum 
culture.
Several rare pathogens were identified in the present study. 
N carnea, less frequently encountered as a human pathogen (32), was 
isolated from two cases of pulmonary infections. In one report, the 
species was isolated from a pulmonary infection in a patient with 
tuberculosis (45). To our knowledge, N crassostreae has not been 
reported as a human pathogen since its isolation in 1998 from Pacific 
oysters (46). This species was isolated from a paravertebral abscess at 
L3-L5 from a patient with a non-Hodgkin’s lymphoma undergoing 
chemotherapy. N testacea, isolated from sputum of a patient with pre-
vious pulmonary tuberculosis in the present study, has been rarely iso-
lated from clinical specimens (47). N asiatica, a rare agent of 
Figure 3) Chest computed tomography scan of an immunocompetent 
patient (case 3). A small area of consolidation in the inferior segment of 
lingual (left lung) caused by Nocardia cyriacigeorgica is apparent
TAble 2
Susceptibility pattern of Nocardia species to most 
common antibiotics (µg/ml)
Case
Organism (genus 
Nocardia) AK MOX CTX SXT lIN IMI bl
1 N cyriacigeorgica 0.5 0.19 0.38 0.016 0.25 0.19 +
2 N cyriacigeorgica 1.5 4 0.75 0.64 0.38 0.19 +
3 N cyriacigeorgica 0.75 6 ND 0.19 0.75 0.75 –
4 N otitidiscaviarum 1 3 >256 12 0.75 >32 +
5 N otitidiscaviarum 1.5 1 >256 0.19 0.5 >32 +
6 N farcinica 2 0.023 1.5 0.064 0.38 0.094 +
7 N farcinica 2 0.047 6 0.5 0.75 1 +
8 N farcinica 0.75 0.064 16 0.5 0.5 0.5 +
9 N carnea 0.19 0.38 2 0.5 0.25 0.38 –
10 N carnea 0.25 0.19 2 0.25 0.094 0.75 –
11 N crassostreae >256 0.38 >256 1.5 0.25 >32 +
12 N testacea 0.38 0.094 1.5 0.38 0.19 0.25 –
13 N asiatica 0.094  >32 0.094 0.08 0.032 0.19 –
AK Amikacin; BL Beta-lactamase; CTX Cefotaxime; IMI Imipenem; LIN 
Linezolid; MOX Moxifloxacin; SXT Trimethoprim-sulfamethoxazole; – Negative; 
+ Positive
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nocardiosis, was first described in 2004, including five strains isolated 
from Asia (48), and six documented clinical isolates causing pneu-
monia or cutaneous infections in patients with HIV and a bone mar-
row recipient (32), and a disseminated infection in HIV patient (31). 
It was isolated in the present study from a breast cancer patient with 
pulmonary infection (case 13). This suggests that, although rarely seen 
in clinical specimens, N asiatica is associated with immune dysfunc-
tion. All patients were treated with appropriate antibiotics and the 
infection resolved without further sequelae.
The organisms are readily aerosolized with dust and the respiratory 
tract remains the main portal of entry, with the majority of patients 
presenting with pulmonary involvement (4,49). Due to its nontypical 
manifestations, nocardiosis is frequently misdiagnosed; the initial diag-
nosis is often pneumonia, tuberculosis or lung abscesses. Radiographic 
presentation may reveal bronchiectasis with pneumonia (Figure 3).
Five immunocompromised patients (Table 1; cases 1, 7, 8, 11 and 
13) were successfully treated with the appropriate antibiotics, but 
case 11 died from a progressive hematological disease. Disseminated 
nocardiosis, particularly in those with central nervous system involve-
ment or bacteremia, has a poor prognosis with a high mortality rate in 
immunocompromised hosts (6,17,22,50).
Accurate identification of Nocardia species is important because 
different species may have different antimicrobial susceptibilities. 
Linezolid had a distinctive activity pattern against all Nocardia spe-
cies (Table 2); these results are in accordance with previously 
reported susceptibility patterns for linezolid (51-53). The data sup-
port linezolid as an alternative for the treatment of nocardiosis. All 
but one isolate of N otitidiscaviarum isolates were susceptibile to 
trimethoprim-sulfamethoxazole. Susceptibility of Nocardia species 
to trimethoprim-sulfamethoxazole is variable; it was reported that 
only 2% of Nocardia isolates (total n=138) in Taiwan were resistant 
(51), compared with a higher resistance rate (42%, total n=765) in 
the United States (53).
In the present study, various Nocardia species exhibited different 
drug susceptibility patterns to cefotaxime and imipenem. The two iso-
lates of N otitidiscaviarum showed a typical multidrug resistance pattern, 
characterized by resistance to cefotaxime and imipenem and positive for 
beta-lactamase activity by nitrocefin disk test. Similar resistance 
patterns were documented in other reports (51-53). N crassostreae was 
resistant to cefotaxime, imipenem and amikacin; however, amikacin was 
uniformly active against all other Nocardia isolates (Table 2). Amikacin 
was demonstrated to be highly active against all tested Nocardia species 
(51,52). Resistance to amikacin is rare and has been reported mainly for 
N transvalensis (53,54); because this is the first report for N crassostreae 
as a human pathogen, susceptibility data were not available in the lit-
erature for clinically isolated strains. N farcinica, one of the predomin-
ant species in the present study, was susceptible to all agents. Despite 
exhibiting beta-lactamase activity by nitrocefin disk test, all isolates 
were susceptibile to cefotaxime and imipenem. One strain was inter-
mediately susceptible to cefotaxime. Resistance to cefotaxime and 
imipenem does not appear to be mediated by beta-lactamase, but 
rather by decreased affinities of penicillin binding-proteins for these 
molecules (55).
Among other species, isolates of the N asiatica, N carnea and N tes-
tacea have been reported only rarely as human pathogens. N asiatica 
was resistant to moxifloxacin but susceptibile to all other five tested 
antimicrobial agents. However, few isolates were tested for suscept-
ibility, which showed a resistance pattern for ciprofloxacin (51,53), 
suggestive of a quinolone resistance profile. This class of antibiotics 
may not be considered for the treatment of infections caused by this 
species.
The present study is the first report of series of Nocardia infection, 
documenting the species prevalent in Qatar. N crassostreae was 
reported for the first time as a human pathogen. The detection of 
multidrug resistance species necessitate molecular identification and 
susceptibility testing, and should be performed for all Nocardia infec-
tions. The disease manifests with different clinical features depending 
on the Nocardia species and underlying conditions. Most patients 
recovered with combined antimicrobial agents. Trimethoprim-
sulfamethoxazole alone or in combination, or sequential with other 
agents, was effective in treating the majority of patients.
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